Aurinia Pharmaceuticals Inc. Operating Lease, Payments
Aurinia Pharmaceuticals Inc. (AUPH) reported Operating Lease, Payments of $1.10 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-02-26
- Aurinia Pharmaceuticals Inc. operating lease, payments for the quarter ending 2024-12-31 was $269.00K, a 8.81% decline year-over-year.
- Aurinia Pharmaceuticals Inc. operating lease, payments for the quarter ending 2024-09-30 was $279.00K, a 1.82% increase year-over-year.
- Aurinia Pharmaceuticals Inc. operating lease, payments for the quarter ending 2024-06-30 was $276.00K, a 2.99% increase year-over-year.
- Aurinia Pharmaceuticals Inc. operating lease, payments for the quarter ending 2024-03-31 was $276.00K, a 4.94% increase year-over-year.
- Aurinia Pharmaceuticals Inc. operating lease, payments for fiscal 2025 was $1.10M, a 0.00% change from fiscal 2024.
- Aurinia Pharmaceuticals Inc. operating lease, payments for fiscal 2024 was $1.10M, a 0.00% change from fiscal 2023.
- Aurinia Pharmaceuticals Inc. operating lease, payments for fiscal 2023 was $1.10M, a 8.33% decline from fiscal 2022.
- Aurinia Pharmaceuticals Inc. operating lease, payments for fiscal 2022 was $1.20M, a 85.76% increase from fiscal 2021.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month | Operating Lease, Payments 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $1.10M 10-K · filed 2026-02-26 | ||||
| 2024-12-31 | $269.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $548.00K derived: sum of 2 quarters · filed 2026-02-26 | $824.00K derived: sum of 3 quarters · filed 2026-02-26 | $1.10M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $279.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $555.00K derived: sum of 2 quarters · filed 2024-11-07 | $831.00K 10-Q · filed 2024-11-07 | $1.13M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-06-30 | $276.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $552.00K 10-Q · filed 2024-08-01 | $847.00K derived: sum of 3 quarters · filed 2026-02-26 | $1.12M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-03-31 | $276.00K 10-Q · filed 2024-05-02 | $571.00K derived: sum of 2 quarters · filed 2026-02-26 | $845.00K derived: sum of 3 quarters · filed 2026-02-26 | $1.11M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2023-12-31 | $295.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $569.00K derived: sum of 2 quarters · filed 2026-02-26 | $837.00K derived: sum of 3 quarters · filed 2026-02-26 | $1.10M 10-K · filed 2026-02-26 | $1.08M 10-K · filed 2024-02-15 |
| 2023-09-30 | $274.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $542.00K derived: sum of 2 quarters · filed 2024-11-07 | $805.00K 10-Q · filed 2024-11-07 | $1.11M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-06-30 | $268.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $531.00K 10-Q · filed 2024-08-01 | $834.00K derived: sum of 3 quarters · filed 2025-02-27 | ||
| 2023-03-31 | $263.00K 10-Q · filed 2024-05-02 | $566.00K derived: sum of 2 quarters · filed 2025-02-27 | |||
| 2022-12-31 | $303.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $1.20M 10-K · filed 2025-02-27 | $1.16M 10-K · filed 2023-02-28 | ||
| 2022-09-30 | $897.00K 10-Q · filed 2023-11-02 | ||||
| 2021-12-31 | $646.00K 10-K · filed 2024-02-15 | ||||
| 2020-12-31 | $267.00K 10-K · filed 2023-02-28 | $232.00K 10-K · filed 2021-02-24 | |||
| 2019-12-31 | $182.00K 10-K · filed 2022-02-28 | $114.00K 10-K · filed 2021-02-24 | |||
| 2018-12-31 | $151.00K 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B |